Bank of America Lowers Bruker (NASDAQ:BRKR) Price Target to $50.00

Bruker (NASDAQ:BRKR - Get Free Report) had its price target dropped by investment analysts at Bank of America from $61.00 to $50.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the medical research company's stock. Bank of America's target price suggests a potential upside of 19.40% from the company's previous close.

Other equities research analysts have also issued research reports about the company. Stifel Nicolaus dropped their price target on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. The Goldman Sachs Group dropped their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Wells Fargo & Company decreased their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Citigroup downgraded shares of Bruker from a "strong-buy" rating to a "hold" rating and lowered their price objective for the stock from $50.00 to $40.00 in a research note on Thursday, May 22nd. Finally, UBS Group reduced their target price on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $52.89.

Bruker Stock Up 2.3%

BRKR stock traded up $0.95 during trading on Thursday, hitting $41.88. 2,417,869 shares of the company's stock traded hands, compared to its average volume of 1,667,312. The firm has a market capitalization of $6.35 billion, a P/E ratio of 80.53, a PEG ratio of 2.66 and a beta of 1.16. The business has a fifty day simple moving average of $38.29 and a two-hundred day simple moving average of $46.85. The company has a quick ratio of 0.74, a current ratio of 1.57 and a debt-to-equity ratio of 1.13. Bruker has a 1 year low of $34.10 and a 1 year high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. Bruker's revenue was up 11.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 EPS. Sell-side analysts anticipate that Bruker will post 2.69 EPS for the current year.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien acquired 2,608 shares of the firm's stock in a transaction on Friday, June 6th. The stock was bought at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the purchase, the chief executive officer now directly owns 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 27.30% of the company's stock.

Institutional Trading of Bruker

Institutional investors and hedge funds have recently bought and sold shares of the business. Pinnacle Bancorp Inc. purchased a new stake in shares of Bruker in the first quarter valued at approximately $29,000. Allworth Financial LP lifted its holdings in shares of Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after buying an additional 745 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Bruker during the 1st quarter worth about $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Bruker by 274.9% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.